Computational identification of the binding mechanism of a triple reuptake inhibitor amitifadine for the treatment of major depressive disorder.

Amitifadine, the only drug ever clinically tested in Phase 3 for treating depression, is a triple reuptake inhibitor (TRI) that simultaneously interacts with human monoamine transporters (MATs) including hSERT, hNET and hDAT. This novel multi-target strategy improves drug efficacy and reduces the toxic side effects of drugs. However, the binding modes accounting for amitifadine's polypharmacological mode of action are still elusive, and extensive exploration of the amitifadine-target interactions between amitifadine and MATs is urgently needed. In this study, a total of 0.63 μs molecular dynamics (MD) simulations with an explicit solvent as well as endpoint binding free energy (BFE) calculation were carried out. MD simulation results identified a shared binding mode involving eleven key residues at the S1 site of MATs for the binding of amitifadine, and the results of the BFE calculations were in good agreement with experimental reports. Moreover, by analyzing the per-residue energy contribution variation at the S1 site of three MATs and additional cross-mutagenesis simulations, the variation in the inhibition ratio of amitifadine between hSERT and two other MATs was discovered to mainly come from non-conserved residues (Y95, I172 and T439 in hNET and Y95, I172, A169 and T439 in hDAT). As the rational inhibition ratio of multi-target drugs among various therapeutic targets was found to be the key to their safety and tolerance, the findings of this study may further facilitate the rational design of more potent but less toxic multi-target antidepressant drugs.

[1]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[2]  Rodrigo Lopez,et al.  Clustal W and Clustal X version 2.0 , 2007, Bioinform..

[3]  D. Case,et al.  Exploring protein native states and large‐scale conformational changes with a modified generalized born model , 2004, Proteins.

[4]  Feng Zhu,et al.  Differentiating physicochemical properties between NDRIs and sNRIs clinically important for the treatment of ADHD. , 2017, Biochimica et biophysica acta. General subjects.

[5]  Feng Zhu,et al.  Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study. , 2016, Physical chemistry chemical physics : PCCP.

[6]  S. Genheden,et al.  The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities , 2015, Expert opinion on drug discovery.

[7]  Benjamin D. Madej,et al.  Lipid14: The Amber Lipid Force Field , 2014, Journal of chemical theory and computation.

[8]  Murugaiah A. M. Subbaiah.  Triple Reuptake Inhibitors as Potential Therapeutics for Depression and Other Disorders: Design Paradigm and Developmental Challenges. , 2018, Journal of medicinal chemistry.

[9]  S. Dulawa,et al.  Identifying fast-onset antidepressants using rodent models , 2017, Molecular Psychiatry.

[10]  William L Jorgensen,et al.  Perspective on Free-Energy Perturbation Calculations for Chemical Equilibria. , 2008, Journal of chemical theory and computation.

[11]  Birgit Schiøtt,et al.  Monoamine transporters: insights from molecular dynamics simulations , 2015, Front. Pharmacol..

[12]  C. Beyer,et al.  Desvenlafaxine Succinate: A New Serotonin and Norepinephrine Reuptake Inhibitor , 2006, Journal of Pharmacology and Experimental Therapeutics.

[13]  Kenneth D. Jordan,et al.  Comparison of Density Functional and MP2 Calculations on the Water Monomer and Dimer , 1994 .

[14]  Michael J. Bodkin,et al.  Accurate calculation of the absolute free energy of binding for drug molecules , 2015, Chemical science.

[15]  S. Korte,et al.  Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited , 2011, Expert opinion on investigational drugs.

[16]  O. Taboureau,et al.  Location of the Antidepressant Binding Site in the Serotonin Transporter , 2009, Journal of Biological Chemistry.

[17]  Feng Zhu,et al.  Clinical Success of Drug Targets Prospectively Predicted by In Silico Study. , 2017, Trends in pharmacological sciences.

[18]  Yang Song,et al.  Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery , 2011, Nucleic Acids Res..

[19]  V. Hornak,et al.  Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.

[20]  Lu Huang,et al.  Update of TTD: Therapeutic Target Database , 2009, Nucleic Acids Res..

[21]  Dan Li,et al.  Assessing the performance of the MM/PBSA and MM/GBSA methods. 6. Capability to predict protein-protein binding free energies and re-rank binding poses generated by protein-protein docking. , 2016, Physical chemistry chemical physics : PCCP.

[22]  P. Kollman,et al.  Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding , 2000 .

[23]  J. Macor,et al.  Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors. , 2014, ACS medicinal chemistry letters.

[24]  J. Bajorath,et al.  Polypharmacology: challenges and opportunities in drug discovery. , 2014, Journal of medicinal chemistry.

[25]  P. Kollman,et al.  A well-behaved electrostatic potential-based method using charge restraints for deriving atomic char , 1993 .

[26]  Tingjun Hou,et al.  Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations , 2011, J. Chem. Inf. Model..

[27]  A. Janowsky,et al.  Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor. , 2003, European journal of pharmacology.

[28]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[29]  Wei Li,et al.  Triple reuptake inhibitors: a patent review (2006 – 2012) , 2014, Expert opinion on therapeutic patents.

[30]  M. Caron,et al.  Structural biology: Antidepressants at work , 2016, Nature.

[31]  B. Blough,et al.  Effects of the triple monoamine uptake inhibitor amitifadine on pain-related depression of behavior and mesolimbic dopamine release in rats , 2015, Pain.

[32]  Bo Li,et al.  NOREVA: normalization and evaluation of MS-based metabolomics data , 2017, Nucleic Acids Res..

[33]  R. Lane.  Antidepressant drug development: Focus on triple monoamine reuptake inhibition , 2015, Journal of psychopharmacology.

[34]  F. Artigas.  Future directions for serotonin and antidepressants. , 2013, ACS chemical neuroscience.

[35]  Eric Gouaux,et al.  X-ray structure of dopamine transporter elucidates antidepressant mechanism , 2013, Nature.

[36]  L. M. Espinoza-Fonseca,et al.  The benefits of the multi-target approach in drug design and discovery. , 2006, Bioorganic & medicinal chemistry.

[37]  Peer Bork,et al.  Interactive Tree Of Life (iTOL): an online tool for phylogenetic tree display and annotation , 2007, Bioinform..

[38]  Zhe Chen,et al.  CFam: a chemical families database based on iterative selection of functional seeds and seed-directed compound clustering , 2014, Nucleic Acids Res..

[39]  Xiao Hua Ma,et al.  Drug Discovery Prospect from Untapped Species: Indications from Approved Natural Product Drugs , 2012, PloS one.

[40]  M. L. Connolly.  Analytical molecular surface calculation , 1983 .

[41]  Angelo D. Favia,et al.  The Molecular Basis for Dual Fatty Acid Amide Hydrolase (FAAH)/Cyclooxygenase (COX) Inhibition , 2015, ChemMedChem.

[42]  Feng Zhu,et al.  Comparison of computational model and X-ray crystal structure of human serotonin transporter: potential application for the pharmacology of human monoamine transporters , 2017 .

[43]  E. Levin,et al.  Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats. , 2015, European journal of pharmacology.

[44]  Giulio Rastelli,et al.  Fast and accurate predictions of binding free energies using MM‐PBSA and MM‐GBSA , 2009, J. Comput. Chem..

[45]  Wei Zhang,et al.  Predicting drug resistance of the HIV‐1 protease using molecular interaction energy components , 2009, Proteins.

[46]  Sylvia Tippmann,et al.  Programming tools: Adventures with R , 2014, Nature.

[47]  Lin Tao,et al.  Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting , 2011, Proceedings of the National Academy of Sciences.

[48]  Weilin Zhang,et al.  Computational Multitarget Drug Design , 2017, J. Chem. Inf. Model..

[49]  Youyong Li,et al.  Assessing the performance of MM/PBSA and MM/GBSA methods. 3. The impact of force fields and ligand charge models. , 2013, The journal of physical chemistry. B.

[50]  Feng Zhu,et al.  Revealing vilazodone's binding mechanism underlying its partial agonism to the 5-HT1A receptor in the treatment of major depressive disorder. , 2017, Physical chemistry chemical physics : PCCP.

[51]  Feng Zhu,et al.  Performance Evaluation and Online Realization of Data-driven Normalization Methods Used in LC/MS based Untargeted Metabolomics Analysis , 2016, Scientific Reports.

[52]  T. Cheatham,et al.  Determination of Alkali and Halide Monovalent Ion Parameters for Use in Explicitly Solvated Biomolecular Simulations , 2008, The journal of physical chemistry. B.

[53]  M. Thase,et al.  Comprehensive Analysis of Remission (COMPARE) with Venlafaxine versus SSRIs , 2008, Biological Psychiatry.

[54]  A. Sandelin,et al.  Interaction of Antidepressants with the Serotonin and Norepinephrine Transporters , 2012, The Journal of Biological Chemistry.

[55]  Feng Zhu,et al.  Differentiating Physicochemical Properties between Addictive and Nonaddictive ADHD Drugs Revealed by Molecular Dynamics Simulation Studies. , 2017, ACS chemical neuroscience.

[56]  Hyeon Joo,et al.  OPM database and PPM web server: resources for positioning of proteins in membranes , 2011, Nucleic Acids Res..

[57]  Tingting Fu,et al.  Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics , 2017, Nucleic Acids Res..

[58]  Sunhwan Jo,et al.  CHARMM‐GUI Membrane Builder toward realistic biological membrane simulations , 2014, J. Comput. Chem..

[59]  E. Nestler,et al.  The Mesolimbic Dopamine Reward Circuit in Depression , 2006, Biological Psychiatry.

[60]  F Zhu,et al.  Homology-free prediction of functional class of proteins and peptides by support vector machines. , 2008, Current protein & peptide science.

[61]  Feng Zhu,et al.  Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study , 2016, Scientific Reports.

[62]  Weiwei Xue,et al.  The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective , 2016, PloS one.

[63]  E. Gouaux,et al.  Neurotransmitter and psychostimulant recognition by the dopamine transporter , 2015, Nature.

[64]  B. Kirtman,et al.  Efficient vector potential method for calculating electronic and nuclear response of infinite periodic systems to finite electric fields. , 2007, The Journal of chemical physics.

[65]  O. Taboureau,et al.  Mutational Mapping and Modeling of the Binding Site for (S)-Citalopram in the Human Serotonin Transporter* , 2009, The Journal of Biological Chemistry.

[66]  Feng Xu,et al.  Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs. , 2015, Pharmacological research.

[67]  Torsten Schwede,et al.  BIOINFORMATICS Bioinformatics Advance Access published November 12, 2005 The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling , 2022 .

[68]  Feng Zhu,et al.  Identification of dual active agents targeting 5-HT1A and SERT by combinatorial virtual screening methods. , 2015, Bio-medical materials and engineering.

[69]  Martti T. Tammi,et al.  Trends in the Exploration of Anticancer Targets and Strategies in Enhancing the Efficacy of Drug Targeting , 2008 .

[70]  Yuzong Chen,et al.  What Contributes to Serotonin-Norepinephrine Reuptake Inhibitors' Dual-Targeting Mechanism? The Key Role of Transmembrane Domain 6 in Human Serotonin and Norepinephrine Transporters Revealed by Molecular Dynamics Simulation. , 2018, ACS chemical neuroscience.

[71]  E. Gouaux,et al.  X-ray structures and mechanism of the human serotonin transporter , 2016, Nature.

[72]  Cheng Zhang,et al.  Nature's contribution to today's pharmacopeia , 2014, Nature Biotechnology.

[73]  M R Barer,et al.  Bacterial viability and culturability. , 1999, Advances in microbial physiology.

[74]  Antonio Lavecchia,et al.  In silico methods to address polypharmacology: current status, applications and future perspectives. , 2016, Drug discovery today.

[75]  Martti T Tammi,et al.  What Are Next Generation Innovative Therapeutic Targets? Clues from Genetic, Structural, Physicochemical, and Systems Profiles of Successful Targets , 2009, Journal of Pharmacology and Experimental Therapeutics.

[76]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[77]  Aloke K. Dutta,et al.  Triple reuptake inhibitors as potential next-generation antidepressants: a new hope? , 2015, Future medicinal chemistry.

[78]  P A Kollman,et al.  Structure and thermodynamics of RNA-protein binding: using molecular dynamics and free energy analyses to calculate the free energies of binding and conformational change. , 2000, Journal of molecular biology.

[79]  B. Schiøtt,et al.  Molecular Basis for Selective Serotonin Reuptake Inhibition by the Antidepressant Agent Fluoxetine (Prozac) , 2014, Molecular Pharmacology.

[80]  Shuang Li,et al.  SVM-Prot 2016: A Web-Server for Machine Learning Prediction of Protein Functional Families from Sequence Irrespective of Similarity , 2016, PloS one.

[81]  P. Kollman,et al.  Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. , 2001, Journal of the American Chemical Society.

[82]  Youyong Li,et al.  Assessing the performance of MM/PBSA and MM/GBSA methods. 4. Accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set. , 2014, Physical chemistry chemical physics : PCCP.